Abstract
| Original language | English |
|---|---|
| Pages (from-to) | e149-e153 |
| Journal | Oncologist |
| Volume | 24 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2019 |
Cite this
}
Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. / van den Ende, Tom; Menting, Stef P.; Ambarus, Carmen A.; van Oijen, Martijn G. H.; van Laarhoven, Hanneke W. M.
In: Oncologist, Vol. 24, No. 4, 2019, p. e149-e153.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye
AU - van den Ende, Tom
AU - Menting, Stef P.
AU - Ambarus, Carmen A.
AU - van Oijen, Martijn G. H.
AU - van Laarhoven, Hanneke W. M.
PY - 2019
Y1 - 2019
N2 - Dermatological adverse events have frequently been reported after immune checkpoint inhibition. When an adverse event occurs during combination of immune checkpoint inhibition with chemotherapy, the question arises which agent is responsible. Unnecessary withdrawal of either chemotherapy or immunotherapy could lead to suboptimal treatment outcomes. Here we report on two patients who developed a cutaneous drug reaction with fever during treatment with paclitaxel, carboplatin, radiotherapy, and PD-L1 inhibition (atezolizumab) for resectable esophageal adenocarcinoma. In the first case atezolizumab was suspected, and in the second paclitaxel. We discuss the clinical manifestation, treatment, and pathophysiology underlying both cases.
AB - Dermatological adverse events have frequently been reported after immune checkpoint inhibition. When an adverse event occurs during combination of immune checkpoint inhibition with chemotherapy, the question arises which agent is responsible. Unnecessary withdrawal of either chemotherapy or immunotherapy could lead to suboptimal treatment outcomes. Here we report on two patients who developed a cutaneous drug reaction with fever during treatment with paclitaxel, carboplatin, radiotherapy, and PD-L1 inhibition (atezolizumab) for resectable esophageal adenocarcinoma. In the first case atezolizumab was suspected, and in the second paclitaxel. We discuss the clinical manifestation, treatment, and pathophysiology underlying both cases.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063288037&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30902915
U2 - 10.1634/theoncologist.2018-0674
DO - 10.1634/theoncologist.2018-0674
M3 - Article
VL - 24
SP - e149-e153
JO - The Oncologist
JF - The Oncologist
SN - 1083-7159
IS - 4
ER -